Discover
Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallEfficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (clinicaltrials.gov) - Mar 19, 2020 - P3; N=200; Not yet recruiting; Sponsor: Sun Pharma Global FZE
IMU-935 / ImmunicImmunic, Inc. reports year end 2019 financial results and highlights recent achievements (PRNewswire) - Mar 16, 2020 - "...We completed enrollment for our phase 2 EMPhASIS trial of our lead compound, IMU-838, for patients with relapsing-remitting multiple sclerosis (RRMS), roughly nine months ahead of our initial plan....We anticipate reporting top-line results in the third quarter of this year and believe that positive data could allow us to move quickly into a pivotal phase 3 trial....The current, single ascending dose trial of IMU-935 is planned to be followed by a phase 1 multiple ascending dose trial in healthy volunteers and a phase 1 trial in patients with mild-to-moderate psoriasis; both are expected to start during the first half of this year."
Tremfya (guselkumab) / J&JMorphoSys presents results for fiscal year 2019 (Yahoo Finance) - Mar 19, 2020 - "Revenues for 2019 include €62.3 million for success-based payments received primarily from Janssen (2018: €19.4 million) including royalties on net sales of Tremfya(R) amounting to €31.8 million for 2019 (2018: €15.4 million)....Janssen is currently conducting a series of clinical studies with Tremfya(R) (guselkumab) in various indications that could generate data during 2020. In 2019, Janssen submitted marketing authorization applications to the U.S. FDA and EMA for Tremfya(R) for the treatment of psoriatic arthritis. Decisions on these applications could potentially be made in 2020."
Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallEfficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (clinicaltrials.gov) - Mar 19, 2020 - P3; N=50; Not yet recruiting; Sponsor: Sun Pharma Global FZE
